-
1دورية أكاديمية
المؤلفون: Berden, Floor A. C., de Knegt, Robert J., Blokzijl, Hans, Kuiken, Sjoerd D., van Erpecum, Karel J. L., Willemse, Sophie B., den Hollander, Jan, van Vonderen, Marit G. A., Friederich, Pieter, van Hoek, Bart, van Nieuwkerk, Carin M. J., Drenth, Joost P. H., Kievit, Wietske
المصدر: Berden , F A C , de Knegt , R J , Blokzijl , H , Kuiken , S D , van Erpecum , K J L , Willemse , S B , den Hollander , J , van Vonderen , M G A , Friederich , P , van Hoek , B , van Nieuwkerk , C M J , Drenth , J P H & Kievit , W 2016 , ' Limited Generalizability of Registration Trials in Hepatitis C : A Nationwide Cohort Study ' , PLoS ONE , vol. 11 , no. 9 , e0161821 . ....
مصطلحات موضوعية: GENOTYPE 1 INFECTION, ADVANCED HEPATOCELLULAR-CARCINOMA, SUSTAINED VIROLOGICAL RESPONSE, TREATMENT-EXPERIENCED PATIENTS, RANDOMIZED CONTROLLED-TRIALS, VIRUS-INFECTION, HCV INFECTION, REAL-WORLD, BOCEPREVIR, TELAPREVIR
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1371/journal.pone.0161821Test
https://hdl.handle.net/11370/4b58c924-bc59-4cfe-9664-200c364ebab3Test
https://research.rug.nl/en/publications/4b58c924-bc59-4cfe-9664-200c364ebab3Test
https://pure.rug.nl/ws/files/39076290/journal.pone.0161821.PDFTest -
2دورية أكاديمية
المؤلفون: Arends, J. E., van der Meer, J. T. M., Posthouwer, D., Kortmann, W., Brinkman, K., van Assen, S., Smit, C., van der Valk, M., van der Ende, M., Schinkel, J., Reiss, P., Richter, C., Hoepelman, A. I. M.
المصدر: Arends , J E , van der Meer , J T M , Posthouwer , D , Kortmann , W , Brinkman , K , van Assen , S , Smit , C , van der Valk , M , van der Ende , M , Schinkel , J , Reiss , P , Richter , C , Hoepelman , A I M , Stichting HIV Monitoring Nederla & ATHENA Natl Observational 2015 , ' Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients ' , Netherlands Journal of Medicine , vol. 73 , no. ....
مصطلحات موضوعية: Boceprevir, direct-acting antiviral agents, hepatitis C, HIV, pegylated interferon-alfa, telaprevir, CHRONIC HEPATITIS-C, GENOTYPE 1 INFECTION, ALPHA-2A PLUS RIBAVIRIN, VIRUS-INFECTION, HCV INFECTION, TRIAL, COHORT
